Palatone · Neurosonos · Clinical Reference
40 Hz gamma entrainment is a non-invasive sensory-stimulation approach developed under the GENUS (Gamma ENtrainment Using Sensory Stimuli) protocol at MIT's Tsai Lab, published in peer-reviewed journals including Nature and Cell. This one-pager summarizes the published evidence, clinical application areas, safety considerations, and reference implementation channels for clinicians and clinical-research audiences.
Gamma oscillations (30–100 Hz) are associated with higher-order cognitive functions including attention, memory binding, and conscious perception. The 40 Hz sub-band has been of particular clinical interest because reduced gamma-band activity has been documented in neurodegenerative conditions — most notably Alzheimer's disease — and the gamma frequency is robust enough to drive measurable neural entrainment through external sensory stimuli. Gamma entrainment using sensory stimuli is therefore of interest as a non-pharmacological, non-invasive adjunct that could plausibly engage the same circuits implicated in disease.
GENUS — Gamma ENtrainment Using Sensory Stimuli — is a research protocol developed at MIT's Tsai Lab and published in peer-reviewed journals including Nature and Cell. Lead investigator: Li-Huei Tsai, PhD (Picower Institute for Learning and Memory). The protocol uses precisely timed 40 Hz stimuli — light flicker, audio tones, and vibration — to drive gamma oscillations in the brain. In multiple studies, 40 Hz gamma entrainment has been associated with measurable changes in neural activity, including in regions affected by Alzheimer's disease. The research was featured on 60 Minutes, bringing the science to a mainstream audience for the first time.
Published evidence and active research programs focus on a small set of indications where gamma-band dysregulation is a documented feature, or where rhythmic / multisensory stimulation has shown a reproducible effect. The table below summarizes condition, frequency band, and the strongest available evidence — pre-clinical, human-pilot, or peer-reviewed clinical-trial.
| Condition | Frequency Band | Evidence Level |
|---|---|---|
| Alzheimer's Disease | 40 Hz gamma (GENUS) | Pre-clinical (Nature, Cell) + human pilot (Alzheimer's & Dementia) |
| Cognitive Decline | 40 Hz gamma (GENUS) | Pre-clinical — same mechanistic basis as Alzheimer's |
| Insomnia | Delta (0.5–4 Hz) + theta onset | Sleep-stage entrainment literature (auditory) |
| Anxiety Disorder | Alpha (8–13 Hz) | Published alpha-entrainment anxiety literature |
| ADHD / Focus | Beta (14–30 Hz) | Studied in ADHD populations; attentional-state entrainment |
| Chronic Pain | Rhythmic auditory stimulation | Pain-gate modulation literature |
| Parkinson's Disease | Rhythmic auditory at gait cadence (RAS) | Established gait-rehabilitation literature |
Not a medical device. Neurosonos is a wellness app, not a medical device, and has not been evaluated or approved by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It is a software tool that implements 40 Hz gamma entrainment as described in published peer-reviewed research. Always consult a physician before using any wellness tool, especially if you have a neurological condition.
Photosensitive epilepsy. Anyone with photosensitive epilepsy, a history of seizures, or other neurological conditions should not use the visual flicker feature without explicit physician guidance. 40 Hz flickering light can trigger seizures in susceptible individuals. Please consult a neurologist before use.
No claims of clinical efficacy for any specific indication are made by Palatone or Neurosonos. The summary above references pre-clinical and early-stage human studies; clinical outcomes for individual patients are not established for any general-purpose 40 Hz gamma-entrainment software deployment.
Reference implementation delivers synchronized 40 Hz stimulation across three sensory channels. All timing is handled automatically — the user selects a protocol and presses play.